



11 - 22 May 2026

**Les Pensées Center for Global Health
Veyrier-du- Lac, France**

LEE/2026/00397

ADVAC is co-organised by the University of Geneva and the Fondation Mérieux with the co-sponsorship of:

- Coalition for Epidemic Preparedness Innovations (CEPI)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Gates Foundation
- International Pediatric Association (IPA)
- Johns Hopkins Bloomberg School of Public Health
- World Health Organization (WHO)

GENERAL INFORMATION

Meeting Venue	Les Pensières Center Global Health, 74290, Veyrier-du-Lac, France +33 450 64 80 80 – contact@lespensieres.org
Hotels	Les Pensières (contact: see above) Hotel Catalpa 34 Av. d'Albigny, 74000 Annecy + 33 04 50 23 02 46
Organization Team	<ul style="list-style-type: none"> • University of Geneva: Flavie Faës/Biata Lysenko: advac@unige.org for questions on the course • Mérieux Foundation: Marianne Gojon Gerbelot/Kristina Ruze : advac-logistique@fondation-merieux.org for questions on logistics (transports/accommodation/flights)
Dates of Meeting	Monday 11th May (9:00 am) – Friday 22nd May 2026 (3:45 pm)
Catering	<ul style="list-style-type: none"> • Lunches and Dinners are provided from 10^h to 22nd of May at the Meeting venue. • Placed meals: during the lunches, speakers will be placed at 1 or 2 per table. Participants are free to sit wherever they like to discuss with the lecturers. • Some meals are upon registration: check course programme and make sure you register on time (onsite only) at Les Pensières Reception Desk! • Food waste: as we are very concerned about food waste, please inform Les Pensières Reception Team at least ½ day before in case you cancel your participation your meal.
Transports	<ul style="list-style-type: none"> • Complimentary Shuttle every day between Hotels and Meeting Venue (see planning onsite) • Public Transports: <ul style="list-style-type: none"> - Getting around by local bus: https://www.sibra.fr/ - French Railway company: https://www.sncf-connect.com/en-en/ - Swiss Railway company: https://www.sbb.ch/en - Flixbus: https://www.flixbus.co.uk/ • Taxis: please ask Les Pensières Reception Team

COURSE PROGRAMME

MONDAY 11 MAY 2026

8:30	Bus from hotels to Les Pensières		
9:00-9:15	Opening and Objectives of the course	Kamel Senouci , Director ADVAC, University of Geneva	Charles Mérieux conf. Room
9:15-09:30	Introduction	Sakurako Marchand , Knowledge Sharing Unit Manager, Mérieux Foundation	
9:30-9:40	Welcome and Logistic briefing	Sandra Angèle , Director, Les Pensières, Fondation Mérieux	
SESSION 1: THE VACCINE JOURNEY: FROM VACCINES TO VACCINATION & THE IMPACT OF VACCINES			<u>Chair:</u> Arnaud Didierlaurent , UNIGE
9:40-10:05	1. From Research to individual protection: The A-to-Z vaccine's journey	Arnaud Didierlaurent and Kamel Senouci , University of Geneva, Switzerland	Charles Mérieux conf. room
10:05-10:25	Discussion		
10:25-10:55	Break		
10:55-11:20	2. Vaccines Preventable Diseases' Burden and Vaccines Impact on Public Health	Kamel Senouci , University of Geneva	
11:20-11:40	Discussion		
11:40-12:05	3. Where are we with vaccine-preventable diseases & immunization coverage worldwide: the state of the immunization	Kate O'Brien , WHO, Geneva	Charles Mérieux conf. room
12:05-12:25	Discussion		
12:25-12:35	Morning evaluations		
12:35-13:35	Lunch	(seated, please check the tables attributed to the speakers)	Restaurant + Ogobara Doumbo room
13:35-14:00	4. Measuring vaccination's impact in populations: Regulatory vs. Public Health Approach to Vaccine Clinical Trial Data	Brad Gessner , Independent expert	
14:00-14:20	Discussion		
14:20-14:45	5. Using vaccines to address a public health problem: the example of Polio eradication immunization strategy	Ananda Bandyopadhyay , Gates Foundation, USA	Charles Mérieux conf. room
14:45-15:05	Discussion		
15:05-15:30	6. GAVI model to support countries immunization program	Marta Tufet , GAVI	
15:30-15:50	Discussion		
15:50-16:00	Afternoon evaluations		
16:00-16:15	Group Picture	Meet Outside!	In the garden
16:15-16:45	Break		
16:45-17:30	Meet your mentor		
17:30-18:30	Self-presentation of participants (background, interests in life...)	Social Event	Nicole Mérieux room
18:30-20:00	Welcome Reception		
20:00	Bus to Hotels		

TUESDAY 12 MAY 2026

8:30 Bus from hotels to Les Pensières

SESSION 2: HOW VACCINES WORK?

Chair:
Kamel Senouci,
Director
ADVAC, UNIGE

09:00-09:25	7. How do vaccines protect? Immune effectors induced by vaccines: Antibodies, B and T cells, mucosal immunity	Christiane Eberhardt , University of Geneva, Switzerland	
09:25-09:45	Discussion		
09:45-10:10	8. How are vaccines' responses elicited? What a vaccinologist should know about the basic aspects of immunological responses	Christiane Eberhardt , University of Geneva, Switzerland	Charles Mérieux conf. room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	9. How to use vaccines' platforms to tailor immune responses?	Arnaud Didierlaurent , University of Geneva, Switzerland	
11:25-11:45	Discussion		
11:45-12:10	10. Non-specific effects of vaccines	Nigel Curtis , The Royal Children's Hospital, Melbourne, Australia (online)	Charles Mérieux conf. room
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo room
14:00-15:30	Interactive Session 1 and Q&A Variability of vaccine responses in the real world	Christiane Eberhardt , University of Geneva, Switzerland & Arnaud Didierlaurent , University of Geneva, Switzerland	Charles Mérieux
15:30-15:55	11. Immunological memory	Rafi Ahmed , Emory University, USA	
15:55-16:15	Discussion		Charles Mérieux
16:15-16:45	Break		Restaurant
16:45-17:10	12. Use and limitations of correlates of immunity in vaccinology	Adam Finn , University of Bristol, UK	Charles Mérieux
17:10-17:30	Discussion		

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 1/3)

Chair: Arnaud
Didierlaurent

17:30-17:55	13. Vaccine market, market shaping and regional initiatives for vaccine production	Georgios Stathopoulos , WHO, Switzerland	Charles Mérieux
17:55-18:15	Discussion		
18:15-18:25	Afternoon evaluations		
18:25-19:15	Soccer, Karaoke, Mölkky, Pétanque....	Social Event	Outside
19:30-21:00	Refreshments and Dinner		Restaurant
21:00	Bus to Hotels		

WEDNESDAY 13 MAY 2026

8:30 Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 2/3)

Chair: Arnaud Didierlaurent
± E. Erbeling,

09:00-09:25	14. Landscape in vaccine and immunization technologies- platform-production (include nasal vaccine)	Emily Erbeling (Independent expert)	
09:25-09:45	Discussion		Charles Mérieux conf. Room
09:45 -10:10	15. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger, IAVI, USA	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	16. From inception to regulatory submission	Rick Malley, Boston Children Hospital, USA	
11:25-11:45	Discussion		
11:45-12:10	17. The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, France	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-13:55	Lunch		Restaurant + O. Doumbo

SESSION 4 – VACCINE REGULATORY

Chair: E. Erbeling

13:55-14:20	18. The role of Regulatory Agencies, Issues and Challenges of submitting a dossier (including content of a dossier)	Marco Cavaleri, EMA, The Netherlands	Charles Mérieux Room
14:20-14:40	Discussion		
14:40-16:10	Small Group Exercise 1 (Part 1): Vaccine Regulatory 4 Groups: <ul style="list-style-type: none"> ○ 1. O. Berger & L. Jodar ○ 2. A. Didierlaurent & V. Gambillara-Fonck ○ 3. O. Rovira & N. Baylor ○ 4. M. Cavaleri & D. Boyce 	Norman Baylor, Biologics Consulting Group, US Ozzie Berger, IAVI, USA, Donna Boyce, Pfizer USA, Marco Cavaleri, EMA, Netherland, Arnaud Didierlaurent, UNIGE, Switzeland, Veronica Gambillara-Fonck, Pureos Bioventures, Switzerland, Luis Jodar (independent expert), Olga Rovira, Kontivax, Belgium.	Check Boards for groups + rooms' assignment
16:10-16:40	Break		Restaurant
16:40-16:55	Small Group Exercise 1 (Part 2): Debriefing	All groups	Charles Mérieux Room
16:55-18:25	Optional lecture: Interactive Session 2 From ideas to implementation - the realities of funding for vaccine research and development in the private sector	DCVMN and IFPMA members Please check group assignments on boards	Charles Mérieux Room + Nicole Mérieux
18:25-18:35	Afternoon evaluations		Charles Mérieux

Special lecture: THE 10th LAMBERT LECTURE

18:35-18:45	Introduction	Paul-Henri Lambert	
18:45-19:10	19. Immune Fitness	John S. Tsang, Yale University, USA	Charles Mérieux room
19:10-19:30	Discussion		
19:30-20:45	Dinner		

20:45

Bus to Hotels

THURSDAY 14 MAY 2026

08:30

Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 3/3)

Chair: Emily
Erbelding

09:00-09:25 **20. Delivering outbreaks vaccine in 100 Days:
What does it take?**

Joseph Simmonds-Issler, CEPI, UK

09:25-09:45 Discussion

09:45-10:45 **Interactive session 3 and Q&A**

What can go wrong in vaccine development?

Panelists:

Rosane Cuber, Bio-Manguinhos, Brazil
Luis Jodar (independent expert)
Rick Malley, Boston Children Hospital, USA
Emily Erbelding (independent expert)
Adam Finn, University of Bristol, UK

Charles
Mérieux
Conf room

10:45-11:00 Break

Restaurant

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)

Chair: Edwin
Asturias

11:00-11:25 **21. A to Z for vaccines clinical trials**

Romina Libster, Fundacion INFANT, Argentina

11:25-11:45 Discussion

11:45-12:10 **22. Clinical trials: an overview of issues to be
considered**

Andrew Pollard, Oxford Vaccine Group, UK

Charles
Mérieux

12:10-12:30 Discussion

12:30 -12:40 Morning Evaluations

12:40-13:25 Lunch

Restaurant

13:25-13:50 **23. Introduction to statistical aspects of clinical trials**

Martha Nason, PATH, USA

13:50-14:10 Discussion

Charles
Mérieux

14:10-16:25 **Small Group Exercise 2:
How to design, recruit volunteers for, and
analyze the results of selected phase II trials
(technique Artcast en CMX)**

7 Groups:

Group 1: S. Aureus: V. Gambillara & B. Gessner
Group 2: Ebola: M. Nason & R. Libster
Group 3: Dengue: N. Baylor & A. Durbin
Group 4: RSV: E. Asturias & K. Talaat
Group 5: Mpox: K. Johansen
Group 6: Typhoid conjugate vaccines: K. Senouci
Group 7: Coronavirus: E. Erbelding

Check Boards
for groups +
rooms'
assignment
(CMX + autres)

16:25-16:55 Break

Restaurant

16:55-17:20 **24. Assessing herd protection and vaccine
effectiveness (and use for licensure)**

John Clemens, International Vaccine Institute (IVI),
Republic of Korea

17:20-17:40 Discussion

Charles
Mérieux

17:40-18:05 **25. Human Challenge Trials or other ways of assessing
vaccine efficacy**

Chris Chiu, Imperial College London, UK

18:05-18:25 Discussion

Charles
Mérieux

18:25-18:35 Afternoon evaluations

18:45-20:00 Dinner

Restaurant +
O.Doumbo room

20:00

Bus to Hotels

FRIDAY 15 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 6 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS

Chair: Kari Johansen

09:00-09:25	26. How do vaccines cause adverse events? (Including Immune-mediated diseases)	Kawsar Talaat , Johns Hopkins Bloomberg School of Public Health, USA	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	27. WHO Guidance on how to detect and manage safety issues	Madhav Balakrishnan , WHO, Switzerland	Conf room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	28. Population-based post-licensure surveillance (including study methodology for signal validation and epi studies)	Kaatje Bollaerts , P95, Belgium	
11:25-11:45	Discussion		Charles Mérieux
11:45-12:10	29. Immunization safety, logistic and vaccine management in vaccination programs (CTC, VVM)	Kamel Senouci , University of Geneva	
12:10-12:30	Discussion		
12:30-12:40	Morning Evaluations		
12:40-14:00	Lunch		Restaurant + Ogobara Doumbo

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)

14:00-14:30	Mentoring		
14:30-16:40	Small group exercise 3: Vaccine trial Phase III planning, implementation, analysis of the study results	7 Groups: Group 1: V. Gambillara Group 2: M. Nason & R. Libster Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbeling	Check Boards for groups + rooms' assignment
16:40-16:50	Afternoon evaluations		
16:50-17:20	Break		Restaurant

Special lecture: THE 18TH PLOTKIN LECTURE

17:20-17:25	Introduction	Edwin Asturias , Children's Hospital Colorado, USA	
17:25-17:50	30. Advancing CMV Vaccine Strategies: From Bench to Bedside	Sallie Permar , Cornell University, USA	Charles Mérieux
17:50-18:10	Discussion		
18:30-20:00	Reception Dinner		Restaurant + O. Doumbo
20:00	Bus to Les Pensières		

SATURDAY 16 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 7 - ETHICAL ISSUES

Chair: Kari Johansen, Public Health Agency, Sweden

09:00-09:25 **31. Applied ethics in immunization programs and practice** **Anuradha Rose**, Christian Medical College of Vellore, India

09:25-09:45 Discussion

Charles Mérieux conf room

09:45-10:10 **32. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines** **Catherine Slack**, University of KwaZulu-Natal, South Africa

10:10-10:30 Discussion

10:30-10:50 Break

Restaurant

10:50-13:00 **Small group exercise 4:**

Facilitators (7 Groups):

Ethical considerations in vaccine trials

Edwin Asturias, Kari Johansen, Anuradha Rose, Louise Henaff, Catherine Slack, Martha Nason, Kawsar Talaat.

Check Boards for groups + rooms' assignment

13:00-13:10 Evaluations of the day

13:10-13:40 Lunch

Take away or eat at the Restaurant

13:40 Bus to Hotels and Free time in the afternoon

18:45 Bus from Hotels to Les Pensières

Dinner upon Registration

Please register at Les Pensières Lobby

Restaurant

20:15 Bus from Les Pensières to Hotels

SUNDAY 17 MAY 2026

18:45 Bus from hotels to Les Pensières (for dinner only)

Dinner upon registration

Please register at Les Pensières Lobby

Restaurant

20:15 Bus from Les Pensières to Hotel

MONDAY 18 MAY 2026

8:30	Bus from hotels to Les Pensières		
09:00-09:10	Ethical considerations in vaccine trials: Recap	Catherine Slack , University of KwaZulu-Natal, South Africa	Charles Mérieux conf. Room
SESSION 8 – DECISION MAKING FOR VACCINES (Part 1/2)			<u>Chair:</u> Louise Henaff
09:10-09:35	33. The decision-making processes for vaccines use: global, regional and local perspectives	Rudzani Muloiwa , University of Cape Town, South Africa	
09:35-09:55	Discussion		Charles Mérieux
09:55-10:20	34. The example of the WHO SAGE decision making processes	Melanie Marti , WHO Geneva, Switzerland	
10:20-10:40	Discussion		
10:40-11:10	Break		Restaurant
11:10-11:35	35. The decision-making processes for vaccines' use: what should experts consider	Kari Johansen , Public Health Agency of Sweden	
11:35-11:55	Discussion		Charles Mérieux
11:55-12:20	36. The role of health economics (including modelling) as a tool in analyzing vaccine policy options	Marc Brisson , Université de Laval, Canada	
12:20-12:40	Discussion		
12:40-12:50	Morning Evaluations		
12:50-13:50	Lunch		Restaurant
13:50-16:00	Small group exercise 5 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.	7 Groups: <ul style="list-style-type: none"> • Group 1: Rotavirus: M. Iturriza • Group 2: HPV: K. Senouci • Group 3: Dengue LMICs: H. Nohynek • Group 4: Zoster: K. Johansen • Group 5: Malaria: K. Neuzil • Group 6: RSV Adults: K. Talbot • Group 7: RSV: J. Englund 	Check rooms' assignments on boards
16:00-16:20	Break		Restaurant
SESSION 9 – UPDATES ON VACCINES (part 1/4)			<u>Chair:</u> Anna Durbin
16:20-16:45	37. Polysaccharide and conjugate vaccines	David Goldblatt , University College London, UK (online)	
16:45-17:05	Discussion		
17:05-17:30	38. Pneumococcal conjugate vaccines: the impact of PCV, its introduction in different populations (including adults & children) and the change in PCV valency stereotypes	Keith Klugman , Gates Foundation, USA (online)	Charles Mérieux conf. Room
17:30-17:50	Discussion		
17:50-18:00	Afternoon evaluations		
18:00-19:00	Book your Mentor		
19:00-20:15	Dinner		Restaurant + O. Doumbo
20:15	Bus to Hotels		

TUESDAY 19 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (part 2/4)

Chair: Anna Durbin

09:00-09:25	39. HPV vaccines	Deborah Watson-Jones , London School of Hygiene and Tropical Medicine & Mwanza Intervention Trials Unit (MITU) Tanzania	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	40. Typhoid vaccines	Kathy Neuzil , Gates Foundation	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	41. Malaria Vaccines	Simon Draper , University of Oxford, UK	
11:25-11:45	Discussion		
11:45-12:10	42. Vaccines against arboviruses (Dengue, Zika, Chikungunya)	Anna Durbin , Johns Hopkins Bloomberg School of Public Health, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:40	Morning evaluations		
12:40-14:00	Lunch		Restaurant + O. Doumbo
14:00-14:25	43. Rotavirus and norovirus vaccines	Miren Iturriza , Gates Foundation	
14:25-14:45	Discussion		Charles Mérieux

SESSION 8 – DECISION MAKING FOR VACCINES (Part 2/2)

Chair: Anna Durbin

14:45-15:45	Small group exercise 6 Sharing recommendations with the Minister of Health	Restitution of the 7 Groups from Exercise 5	Charles Mérieux
15:45-16:15	Break		Restaurant

SESSION 9 – UPDATES ON VACCINES (part 3/4)

Chair: Anna Durbin

16:15-16:40	44. Annual strain adaptation: the examples of Flu and COVID vaccines	Kanta Subbarao , Université de Laval, Canada	
16:40-17:00	Discussion		
17:00-17:25	45. Combination vaccines	Hanna Nohynek , Finnish Institute for Health and Welfare, Finland	Charles Mérieux
17:25-17:45	Discussion		
17:45-18:10	46. Vaccines for Non-Communicable Diseases	Joachim Hombach , University of Geneva, Switzerland	
18:10-18:30	Discussion		
18:30 - 18:40	Afternoon evaluation		
18:40-19:10	Debate “Mandatory vs voluntary vaccination”	Rudzani Muloiwa & Kathy Neuzil	Charles Mérieux
19:10-20:30	Dinner		Restaurant + O. Doumbo
20:30	Bus to Hotels		

WEDNESDAY 20 MAY 2026

08:30 Bus from Hotels to les Pensières

SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES

Chair: **Hanna Nohynek**

09:00-09:25	47. RSV and GBS vaccines	Janet Englund, University of Washington/Seattle Children's Hospital Seattle, USA	Charles Mérieux conf. Room
09:25-09:45	Discussion		
09:45-10:10	48. Vaccination and pregnancy and early life	Christiane Eberhardt, University of Geneva, Switzerland	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	49. Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias, Children's Hospital Colorado, USA	
11:25-11:45	Discussion		
11:45-12:10	50. Vaccine responses and efficacy in the elderly	Keipp Talbot, Vanderbilt University, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	51. Vaccination in immuno-compromised individuals	Christoph Berger, University of Basel, Switzerland	
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:55	Lunch		Restaurant

15:00-16:30 PARALLEL SESSIONS (rotation of two 45 min-Sessions)

1. National decision-making for immunization programmes	Louise Henaff, Rudzani Muloiwa, Cape Town University	Check Board for Assignment into group exercises
2. Clinical vaccinology: from Guidelines to Patient Care	Alessandro Diana, Christiane Eberhardt, University Hospitals of Geneva (HUG)	
3. New approaches towards vaccination e-registries	Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden	
4. Monitoring immunization program performance	Jan Grevendonk, WHO Geneva	
5. Global and regional data for Global Strategies	Laure Dumolard, WHO Geneva	
6. AEFI causality assessment	Madhav Balakrishnan, WHO, Geneva	

16:30-16:45 Break Restaurant

SESSION 11 – REACHING SPECIFIC GROUPS (part ½)

Chair: **Kamel Senouci**

16:45-17:10	52. How to better reach the zero-dose or under-vaccinated children in LMICs	Kamel Senouci, University of Geneva	
17:10-17:30	Discussion		Charles Mérieux conf. Room
17:30-17:40	Afternoon evaluations		
18:00-19:15	Dinner upon registration		Restaurant

19:15 Bus to Hotels

THURSDAY 21 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (Part 4/4)

Chair: Edwin Asturias

09:00-09:25	53. Cholera vaccines	Alejandro Cravioto, National Autonomous University of Mexico	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	54. Meningococcal vaccines	Shamez Ladhani, UKHSA, UK	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	55. Tuberculosis vaccines	Helen McShane, University of Oxford, UK	
11:25-11:45	Discussion		Charles Mérieux

SESSION 11 – REACHING SPECIFIC GROUPS (part 2/2)

Chair: Kamel Senouci

11:45-12:10	57. The determinants of vaccine acceptance	Eve Dubé, Université de Laval, Canada	
12:10-12:30	Discussion		
12:30-12:55	56. Life-course vaccines: how to better reach individuals from childhood to elderly?	Pierre Van Damme, University of Antwerp, Belgium (online)	Charles Mérieux
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25 – 14:25	Lunch		Restaurant + O.DUmbo

SESSION 12 – COMMUNICATION AND VACCINE HESITANCY (part ½)

14:25-15:25	Small group exercise 7: Identifying & Collecting Evidence to advise on demand generation	Eve Dubé, Naveen Thacker, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson	Several rooms: please check on boards
15:25-16:25	Interactive Session 4 and Q&A	Lucien De Brot and Darius Beucler, OPSCI, France	Charles Mérieux
	Vaccination in the face of information chaos: from Analysis to Strategic Response		
16:25-16:35	Afternoon evaluations		
16:35	Break		Restaurant
16:45	Bus departure from les Pensières to hotels (check board for return bus from hotels to the Menthon Castle)		Meet at the Reception Lobby
18:15	Bus departure from Les Pensières to Château de Menthon Saint Bernard for visit of the castle and Gala Dinner		
22:00 and 23:45	Buses from Château de Menthon to les Pensières & Hotels		

FRIDAY 22 MAY 2026

08:30 Bus from hotels to Les Pensières

SESSION 12: COMMUNICATION AND VACCINE HESITANCY (part 2/2)

Chair:
Louise Henaff,

09:00-09:20	58. Introduction to Communication Strategy design	Louise Henaff, University of Geneva	Charles Mérieux conf. Room
09:20-10:30	Small Group Exercise 8: Communication strategy design	Lucien De Brot, Darius Beucler, Kamel Senouci, Louise Henaff, Eve Dubé, Naveen Thacker	Several rooms: check on boards
10:30-11:00	Break		Restaurant
11:00-11:25	59. Introduction to Empathetic Communication	Philipp Schmid, JITSUVAX, Netherlands	Charles Mérieux
11:25-12:30	Small Group Exercise 9: Empathetic Communication, Role play	Philipp Schmid, Eve Dubé, Alessandro Diana, Kamel Senouci, Louise Henaff, Rudzani Muloiwa, Angus Thomson	Several rooms: check on boards

SESSION 13: INNOVATION ON IMMUNIZATION

Chair:
Kamel Senouci

12:30-12:55	60. Artificial Intelligence and vaccines	Edwin Asturias, Children's Hospital Colorado, USA	Dr. Charles Mérieux conf. Room
12:55-13:15	Discussion		
13:15-13:25	Morning evaluations		
13:25-14:40	Lunch		Restaurant + O. Doumbo

SESSION 14: CLOSING

14:40-15:00	Final evaluation and Post course assessment		Charles Mérieux
15:00-15:45	Diploma ceremony, awarding of CME credits and closure of the course	Kamel Senouci, Director, ADVAC, University of Geneva	
16:30	Bus from Les Pensières to hotels (check boards for Schedule)		

OPTIONAL LECTURE

WEDNESDAY 13 MAY 2026

SESSION 3: VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL

Chair: Kamel Senouci, Director ADVAC, University of Geneva

16:45-18:15

Interactive Session 2

From ideas to implementation - the realities of funding for vaccine research and development in the private sector

Two 45-minutes sessions (2 groups switching)

Group A: starting with Fiocruz

Group B: starting with Luis Jodar

Luis Jodar, independent expert

Rosane Cuber, Bio-Manguinhos Brazil

Room Charles Mérieux

+

Room Nicole Mérieux